DEA Okays Factory-Scale Magic Mushroom Drug Making?
Published Date: 4/18/2025
Notice
Summary
Patheon API Services Inc. wants to make big batches of certain controlled drugs like psilocybin and methadone to help with medical research. If you have thoughts or want a hearing, you have until June 17, 2025, to speak up. This move mainly affects drug makers and researchers, with no immediate cost changes announced.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Application to Bulk‑Manufacture Specific Controlled Drugs
Patheon API Services Inc. applied on February 5, 2025 to be registered to bulk manufacture these controlled substances: Dimethyltryptamine (drug code 7435, Schedule I), Psilocybin (7437, Schedule I), Psilocyn (7438, Schedule I), Amphetamine (1100, Schedule II), and Methadone (9250, Schedule II). The company states it plans to bulk manufacture the listed substances to support the clinical trials of their customers, and the registration would not authorize any other activities for these drug codes.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20757, Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products
The DEA is removing the special exemption for certain inactive butalbital prescription products that are no longer made or sold. Starting November 9, 2026, these products won’t be treated as exempt under drug laws anymore, but active products stay the same. This change mainly affects drug companies and pharmacies handling these old products, with no new costs for active medicines.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-06706, Bulk Manufacturer of Controlled Substances Application: Stepan Company
Stepan Company wants to get official permission to make large amounts of cocaine and ecgonine, which are controlled substances. This affects other manufacturers and the public, who can share their thoughts or ask for a hearing by June 17, 2025. The company will use these substances mainly to make other products or sell to customers, with no extra activities allowed.
Next: 2025-06708, Notice of Availability; Service Contract Inventory
The Department of Justice just shared its 2023 list of service contracts over $25,000, showing how they use contractors and federal workers. This helps make sure the right balance is kept and money is spent wisely. If you work with or watch DOJ contracts, this update is your go-to for transparency and smart spending insights.